Treatment of Systemic Mastocytosis in Mast Cell Leukemia with KIT D816V Mutation

Clinical Scenario

This protocol addresses systemic mastocytosis presenting as mast cell leukemia (MCL) in patients with a confirmed KIT D816V mutation — a high-risk subtype associated with an aggressive clinical course and distinct management needs.

Defining Features

Mast cell leukemia (MCL) KIT D816V mutation

The combination of mast cell leukemia and the KIT D816V mutation identifies a subgroup of systemic mastocytosis patients for whom targeted treatment planning is essential. This presentation informs both eligibility criteria and the therapeutic approach taken.

Treatment Approach

For appropriate candidates — including those with acute mast cell leukemia — an intensive cellular-based intervention forms part of the treatment strategy. Full candidate criteria, sequencing, and the complete regimen are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Midostaurin is appropriate both as first-line treatment, particularly in MCL patients, as well as salvage treatment in patients progressing after interferon-α or cladribine therapy.

Other potential candidates include ASM patients with relapsed/refractory disease or those with “acute MCL.”

DOI: 10.1002/ajh.26962

View source ↗